The ocular drug delivery industry focuses on delivering medication effectively to treat various eye conditions. It includes companies developing innovative technologies such as sustained-release implants and novel formulations that enhance drug absorption. This field is growing rapidly, driven by the increasing prevalence of visual impairments and demand for improved patient compliance. Advancements in biomaterials and drug delivery systems will likely reshape treatment paradigms, facilitating painless long-term therapies. The rise of targeted therapies and the aging population are propelling further investments and innovations, making this sector one to watch in the pharmaceutical landscape.

This listing highlights 28 companies dedicated to ocular drug delivery, which range in size from small startups to larger corporations. Headquartered in various regions, including North America, Europe, and Asia, these firms are founded between 1964 and 2023. The companies specialize in unique therapeutic solutions, such as sustained-release devices for glaucoma and innovative eye drops. Their diverse focus showcases a shared vision of improving eye health through technology and research, positioning them within an industry eager for breakthrough developments.

Read on to explore the top ocular drug delivery companies.

Top 28 Ocular Drug Delivery Companies

1. Ripple Therapeutics

• Website: rippletherapeutics.com
• Ownership type: Private
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 100%
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: ripple-therapeutics

Ripple Therapeutics, founded in 2020 and based in Toronto, Ontario, is a private biotechnology company dedicated to advancing ophthalmic therapeutics. The firm specializes in controllable, sustained drug delivery systems, aiming to improve treatment outcomes for conditions such as diabetic macular edema and glaucoma. Their flagship product, the IBE-814 IVT implant, is a patented intravitreal dexamethasone prodrug designed for extended release, with a duration of 6 to 9 months. Ripple has made significant strides in clinical trials, including a Phase 2 trial for IBE-814, and has established partnerships for product development and commercialization. The company has raised over $25 million in seed and Series A funding, indicating strong investor interest and confidence in their innovative approach to ocular drug delivery.

2. Laboratoires Théa

• Website: laboratoires-thea.com
• Ownership type: Family Owned
• Headquarters: Clermont-Ferrand, Auvergne-Rhône-Alpes, France
• Employee distribution: France 81%, Other 19%
• Founded year: 1993
• Headcount: 1001-5000
• LinkedIn: laboratoiresthea

Laboratoires Théa, founded in 1993 and based in Clermont-Ferrand, France, is a family-owned pharmaceutical company dedicated to ophthalmology. With a workforce of approximately 858 employees, Théa has established itself as a significant entity in the field of eye care. The company specializes in the research, development, and commercialization of a broad array of ophthalmic products, including medications and medical devices. Their primary clientele consists of healthcare professionals seeking effective treatments for various ocular conditions. Notably, Théa has pioneered the development of preservative-free eye care products, addressing the adverse effects of preservatives on eye health. The company operates in over 75 countries, with a strong presence in Europe and expanding markets in North Africa and Latin America. Their commitment to innovation and quality is evident in their extensive product range, which caters to multiple eye health issues, including dry eye, glaucoma, and infections.

3. Re-Vana Therapeutics

• Website: revanatx.com
• Ownership type: Venture Capital
• Headquarters: Belfast, Northern Ireland, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series A, $12.1M, November 2022
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: re-vana-ltd

Re-Vana Therapeutics is a biotechnology company based in Belfast, Northern Ireland, focused on advancing ocular drug delivery systems. Founded in 2016, the company has developed innovative technologies such as EyeLief and OcuLief, which are designed to provide sustained-release therapeutics for serious eye diseases. These biodegradable implants aim to enhance patient compliance by reducing the frequency of drug administration, a common issue in ocular treatments. Re-Vana's technologies are particularly significant in addressing conditions like macular degeneration and glaucoma, which are major contributors to blindness. The company has attracted venture capital funding, including a Series A round of approximately $11.9 million in late 2022, which underscores its potential in the ocular drug delivery market. Re-Vana is actively collaborating with pharmaceutical companies to explore the feasibility of their technologies, positioning itself as a notable entity in the ocular therapeutics space.

4. EyeD Pharma

• Website: eyedpharma.com
• Ownership type: Venture Capital
• Headquarters: Seraing, Wallonia, Belgium
• Employee distribution: Belgium 100%
• Latest funding: $51.0M, December 2021
• Founded year: 2012
• Headcount: 51-200
• LinkedIn: eyed-pharma

EyeD Pharma, founded in 2012 and based in Seraing, Belgium, is a clinical stage pharmaceutical company dedicated to enhancing the lives of patients suffering from ophthalmic diseases. The company focuses on unmet medical needs, particularly in the areas of glaucoma and dry eye, by developing innovative therapeutic solutions that utilize sustained release polymeric micro-implants and inserts. EyeD Pharma aims to improve patient compliance and minimize side effects associated with traditional treatments. With a team of over 50 professionals, the company manages the entire development process internally, from concept to market. EyeD Pharma has also secured significant funding, amounting to over 50 million euros, which supports its research and development efforts. Their pipeline includes products currently in various stages of clinical development, showcasing their commitment to addressing critical health challenges in ophthalmology.

5. Medivis

• Website: medivis.it
• Ownership type: Private
• Headquarters: Tremestieri Etneo, Sicily, Italy
• Employee distribution: Italy 100%
• Founded year: 2000
• Headcount: 11-50
• LinkedIn: medivis

Medivis srl, based in Tremestieri Etneo, Sicily, Italy, is a private medical product manufacturer established in 2000. The company is dedicated to developing innovative ophthalmic therapies and drug delivery systems. Medivis focuses on research and development, creating effective treatments for ocular conditions. Their product offerings include advanced drug delivery systems that utilize biomolecules with pharmacological action in ophthalmic therapy. Medivis has made significant strides in the field, being the first to patent low-concentration iodine-povidone ophthalmic compositions and to explore the modulation of the microbiome in ocular therapy. The company has received accolades for its innovative approaches, including the S.O.I. Innovation and Research Award in 2017 and recognition from Intesa San Paolo and Sole 24 Ore as one of the 'Imprese Vincenti' in 2020 and 2021. Medivis is ISO 13485 and ISO 9001 certified, ensuring compliance with quality standards in the medical device industry. Their ongoing projects and collaborations further highlight their commitment to addressing unmet needs in ocular health.

6. EyeCRO

• Website: eyecro.com
• Ownership type: Private
• Headquarters: Oklahoma City, Oklahoma, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: eyecro

EyeCRO, founded in 2005 and based in Oklahoma City, Oklahoma, is a private company dedicated to advancing ophthalmic research. With a team of 18 employees, EyeCRO specializes in preclinical studies and innovative drug delivery systems tailored for the eye. They serve a wide range of clients, including over 400 pharmaceutical and biotech firms, helping them develop and test new therapies for various eye conditions. EyeCRO's MiDROPS® technology represents a significant advancement in ocular drug delivery, allowing for the formulation of high concentrations of lipophilic drugs in stable microemulsions. This technology is designed to improve the efficacy of drug delivery to both the anterior and posterior segments of the eye. The company is also accredited by AAALAC and registered with the USDA, ensuring high ethical standards in their research practices. EyeCRO's commitment to ophthalmic research is further demonstrated by their extensive experience and the variety of research models they offer, which cover numerous eye conditions.

7. Eye-go A/s

• Website: eye-go.com
• Ownership type: Private
• Headquarters: Frederiksberg, Frederiksberg, Denmark
• Employee distribution: Denmark 100%
• Founded year: 2015
• Headcount: 1-10
• LinkedIn: eye-go-labs

Eye-go A/s, based in Frederiksberg, Denmark, is a private MedTech company founded in 2015. The company specializes in developing innovative ophthalmic drug delivery systems, with a particular focus on their flagship product, MistGo®. This system is designed to provide a more precise and user-friendly alternative to conventional eye drops, which have been criticized for their inefficiency and potential for user error. Eye-go's technology aims to enhance patient compliance by offering a microdosing solution that minimizes the risk of overmedication and contamination. The company primarily serves individuals requiring eye care treatments, positioning itself as a significant player in the ocular drug delivery sector. Eye-go A/s operates entirely within Denmark and has a small team of experienced professionals dedicated to advancing eye care solutions.

8. Arctic Vision Ltd.

• Website: arcticvision.com
• Ownership type: Venture Capital
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 100%
• Latest funding: Series B, $100.0M, March 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: arcticvision

Arctic Vision Ltd. is an ophthalmic biotech company based in Shanghai, China, founded in 2019. The company specializes in breakthrough therapies for eye diseases, focusing on innovative products that address significant clinical needs in ophthalmology. Their notable offerings include the Suprachoroidal Space Injection Therapy ARVN001, aimed at treating uveitic macular edema, and the iTEAR® Tear Neurostimulation Device, designed to enhance tear production for patients suffering from dry eye symptoms. Arctic Vision is supported by top-tier life sciences investors and is led by a team of industry veterans with extensive experience in research and development, as well as commercialization of ophthalmic products. The company raised $100 million in a Series B funding round in March 2021, which underscores its growth potential and commitment to advancing ocular therapies.

9. AffaMed Therapeutics

• Website: affamed.com
• Ownership type: Venture Capital
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 71%, United States (USA) 20%, Canada 5%, Other 5%
• Latest funding: Series B, $170.0M, March 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: affamed-therapeutics

AffaMed Therapeutics, founded in 2019 and based in Shanghai, China, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics and medical devices for ophthalmology. The company aims to meet critical unmet medical needs in eye care, particularly in Greater China and other Asian markets. AffaMed has a robust pipeline of ophthalmic products, including DEXTENZA, which has recently received attention for its application in treating ocular inflammation and pain following ophthalmic surgery. The company has successfully secured significant funding, with a Series B round raising $170 million in 2021, which underscores investor confidence in their vision and capabilities. With a team experienced in clinical development and regulatory affairs, AffaMed is well-positioned to advance its therapeutic solutions in the ophthalmic field.

10. SpyGlass Pharma, Inc.

• Website: spyglasspharma.com
• Ownership type: Venture Capital
• Headquarters: Aliso Viejo, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $90.0M, July 2023
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: spyglasspharma

SpyGlass Pharma, Inc. is an ophthalmic biotechnology company based in Aliso Viejo, California, established in 2019. The company specializes in innovative drug delivery solutions aimed at enhancing the treatment of cataracts and glaucoma. Their primary offering, the SpyGlass Pharma Drug Delivery Platform, is designed to be implanted with intraocular lenses during cataract surgery, providing a controlled release of medication over an extended period. This platform targets the critical need for consistent medication adherence in glaucoma patients, as it allows for sustained drug delivery independent of patient behavior. SpyGlass Pharma has recently raised $90 million in Series C funding, reflecting strong investor interest in their technology and its potential to improve patient outcomes. The company is actively involved in clinical trials to validate the safety and efficacy of their drug delivery system, positioning itself as a significant player in the ocular drug delivery market.

11. Aerie Pharmaceuticals

• Website: aeriepharma.com
• Ownership type: Corporate
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: Ireland 60%, United States (USA) 36%, Japan 4%
• Latest funding: $770.0M, August 2022
• Founded year: 2005
• Headcount: 501-1000
• LinkedIn: aerie-pharmaceuticals

Aerie Pharmaceuticals, founded in 2005 and based in Durham, North Carolina, is a pharmaceutical company dedicated to developing innovative therapies for eye diseases. The company specializes in creating advanced drug delivery systems, particularly for conditions like glaucoma and retinal diseases. Aerie's product portfolio includes several promising candidates that utilize sustained-release technology, aiming to enhance patient adherence to treatment regimens. Their focus on research and development is underscored by a significant funding round of $770 million in August 2022, which supports their ongoing efforts to bring new therapies to market. Aerie's commitment to ocular health positions it as a notable entity in the eye care industry, particularly in the area of ocular drug delivery.

12. BBB Therapeutics

• Website: bbbtherapeutics.com
• Ownership type: Private
• Headquarters: Leiden, South Holland, Netherlands
• Founded year: 2003
• Headcount: 11-50
• LinkedIn: to-bbb

2-BBB Medicines B.V., also known as BBB Therapeutics, is a biotechnology firm based in Leiden, Netherlands, founded in 2003. The company specializes in creating innovative drug delivery systems aimed at treating brain and eye diseases. Their proprietary G-Technology® is a CNS-targeted liposome formulation that enhances the delivery of pharmaceuticals across the blood-brain and blood-retina barriers. This technology is particularly relevant for addressing significant medical needs in oncology and neuro-inflammation. BBB Therapeutics has developed several lead programs, including LP-DF003, which targets hereditary retinal degeneration, showcasing their commitment to ocular health. The company operates through strategic partnerships to advance its clinical programs, reflecting a collaborative approach to drug development in the biopharmaceutical industry.

13. PolyActiva

• Website: polyactiva.com
• Ownership type: Venture Capital
• Headquarters: Melbourne, Victoria, Australia
• Employee distribution: Australia 100%
• Latest funding: Other (Grant), $988,000, May 2024
• Founded year: 2010
• Headcount: 11-50
• LinkedIn: polyactiva

PolyActiva, based in Melbourne, Australia, is an ophthalmic device manufacturer that focuses on creating biodegradable implants for sustained drug delivery. Founded in 2010, the company aims to enhance treatment outcomes for patients suffering from ocular diseases, particularly glaucoma. Their proprietary Prezia technology allows for precise and controlled drug delivery, addressing the common issue of poor patient adherence to traditional therapies. PolyActiva has been actively involved in clinical trials, recently reporting positive results for their biodegradable ocular implants. The company has also secured funding, including a $1.5 million grant in May 2024, to advance their product pipeline, which includes implants designed to reduce intraocular pressure and prevent postoperative infections. With a dedicated team and a clear mission, PolyActiva is positioned to make significant contributions to the field of ophthalmology.

14. Visus Therapeutics, Inc.

• Website: visustx.com
• Ownership type: Corporate
• Headquarters: Seattle, Washington, United States (USA)
• Latest funding: December 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: visus-therapeutics

Visus Therapeutics, Inc., based in Seattle, Washington, is a clinical-stage pharmaceutical company dedicated to advancing innovative therapies for eye health. Founded in 2019, the company is focused on developing ophthalmic treatments that address significant vision challenges faced by millions. Their flagship product, BRIMOCHOL, is an investigational eye drop designed to correct presbyopia, a condition that affects near vision in adults, particularly those over 40. The formulation combines two established FDA-approved drugs, carbachol and brimonidine tartrate, to create a unique pupil-modulating effect. This innovative approach aims to enhance visual clarity for everyday tasks, such as reading and using digital devices. Visus operates through rigorous clinical trials, with positive data emerging from their Phase 3 studies, indicating a strong commitment to advancing ocular drug delivery solutions. The company is staffed by a team of industry veterans with extensive experience in eye care pharmaceuticals, further solidifying its position in the market.

15. Alkeus Pharmaceuticals, Inc.

• Website: alkeuspharma.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $150.0M, June 2023
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: alkeus-pharmaceuticals-inc-

Alkeus Pharmaceuticals, Inc., founded in 2010 and based in Cambridge, Massachusetts, is a biotechnology firm dedicated to developing innovative therapies for degenerative eye diseases. The company is particularly focused on Stargardt disease, a genetic condition that leads to vision loss, and Geographic Atrophy, a severe form of age-related macular degeneration. Their primary investigational product, Gildeuretinol (ALK-001), is designed to address the root causes of these diseases by reducing the toxic effects of vitamin A dimerization in the eye. Alkeus has made significant strides in clinical research, with multiple trials underway to evaluate the efficacy and safety of Gildeuretinol. In June 2023, they secured $150 million in Series B funding to support their rapid path to market, highlighting their commitment to bringing effective treatments to patients in need. The company is actively working to submit a New Drug Application (NDA) for Gildeuretinol in 2024, further solidifying its role in the ocular drug delivery industry.

16. Nevakar Inc.

• Website: nevakar.com
• Ownership type: Private Equity
• Headquarters: Bridgewater, New Jersey, United States (USA)
• Employee distribution: United States (USA) 80%, India 20%
• Latest funding: $50.0M, June 2019
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: nevakar-llc

Nevakar Inc., founded in 2015 and based in Bridgewater, New Jersey, is a private equity-backed biopharmaceutical company. The firm is dedicated to developing and commercializing innovative ophthalmic and injectable products. Their focus is on addressing unmet medical needs, particularly in the treatment of pediatric myopia through their subsidiary, Vyluma. Vyluma is currently advancing its investigational product, NVK002, a preservative-free low-dose atropine eye drop aimed at slowing the progression of myopia in children. This product is undergoing FDA review, highlighting Nevakar's active role in the ocular drug delivery sector. Additionally, Nevakar has received significant funding, with a reported amount of $50 million in June 2019, which supports their ongoing research and development efforts in the ophthalmic space.

17. Alfa Intes Industria Terapeutica Splendore

• Website: alfaintes.it
• Ownership type: Private
• Headquarters: Casoria, Campania, Italy
• Employee distribution: Italy 100%
• Founded year: 1964
• Headcount: 51-200
• LinkedIn: alfa-intes-industria

Alfa Intes Industria Terapeutica Splendore s.r.l., founded in 1964 and based in Casoria, Campania, Italy, is a private pharmaceutical company dedicated to the production and distribution of ophthalmic products. With a workforce of approximately 140 employees, the company has built a solid reputation in the ophthalmology sector. They offer a wide array of products, including medications, medical devices, and nutraceuticals aimed at enhancing eye health and treatment outcomes. Alfa Intes operates both nationally and internationally, ensuring that healthcare professionals have access to their innovative solutions. Their commitment to quality and innovation is evident in their extensive product line, which addresses various ocular conditions, including infections, inflammation, and dry eye syndrome. The company also engages in educational initiatives through Alfa Academy, providing training and resources for healthcare professionals in the field of ophthalmology.

18. EyeBio

• Website: eyebiotech.com
• Ownership type: Corporate
• Headquarters: London, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 59%, United States (USA) 41%
• Latest funding: $3.0B, May 2024
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: eyebio

EyeBio, founded in 2021 and based in London, is a biotechnology company dedicated to developing innovative therapies for eye diseases. The company is particularly focused on retinal conditions, with its lead product, Restoret, currently in clinical trials. EyeBio's mission is to protect, restore, and improve vision for patients suffering from sight-threatening conditions. The company was co-founded by experienced leaders in ophthalmology, including Dr. David Guyer and Dr. Anthony P. Adamis, who have a history of successful drug development in this field. EyeBio has attracted significant investment, raising $65 million in a Series A funding round in early 2022, which has enabled them to advance their research and development efforts. Recently, EyeBio was acquired by Merck, further solidifying its position in the industry and enhancing its capabilities to deliver new therapeutic solutions.

19. Avedro, Inc.

• Website: avedro.com
• Ownership type: Corporate
• Headquarters: Waltham, Massachusetts, United States (USA)
• Latest funding: August 2019
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: avedro-inc

Avedro, Inc., based in Waltham, Massachusetts, is a corporate entity that specializes in medical technology for ophthalmic diseases. Founded in 2007, the company has carved a niche in the eye care industry with a focus on corneal cross-linking and glaucoma therapies. Avedro is known for its innovative products, including Photrexa and the KXL System, which are essential for the treatment of progressive keratoconus. As a subsidiary of Glaukos Corporation, Avedro benefits from a strong backing in research and development, ensuring that it remains at the forefront of advancements in ocular drug delivery. The company is dedicated to improving patient care through its cutting-edge solutions and has established itself as a key player in the ophthalmic market.

20. Kobec Hs

• Website: kobeconline.com
• Ownership type: Private
• Headquarters: Lahore, Punjab, Pakistan
• Employee distribution: Pakistan 100%
• Founded year: 1998
• Headcount: 51-200
• LinkedIn: kobec-hs

Kobec Hs, officially known as KOBEC Health Sciences, is a private pharmaceutical company based in Lahore, Punjab, Pakistan. Founded in 1998, the company has carved out a niche in the healthcare sector by focusing on innovative ocular products. Their portfolio includes a range of specialty pharmaceuticals designed to improve patient care, particularly in the field of ophthalmology. Kobec Hs has successfully launched several products, such as Tearkool, an ocular lubricant for dry eye syndrome, and XEMOX, an antibiotic solution for bacterial conjunctivitis. The company actively participates in industry events, showcasing its commitment to advancing ocular health. With a dedicated team of professionals, Kobec Hs aims to address the needs of healthcare providers and patients alike, ensuring that their products meet high standards of quality and efficacy.

21. OFFHEALTH S.p.A.

• Website: offhealth.it
• Ownership type: Private
• Headquarters: Florence, Tuscany, Italy
• Employee distribution: Italy 100%
• Founded year: 2014
• Headcount: 51-200
• LinkedIn: offhealth-oftalmica-farmaceutica-italia

OFFHEALTH S.p.A., founded in 2014 and based in Florence, Tuscany, Italy, is a private healthcare company dedicated to the field of ophthalmology. With a workforce of around 63 employees, the company develops a range of products including integrators, medical devices, and pharmaceuticals specifically designed to enhance eye health. OFFHEALTH serves both healthcare professionals and consumers, providing solutions for various eye conditions through innovative research and development. Their commitment to research is evident in their active projects and scientific publications, which aim to advance the understanding and treatment of ocular diseases. The company also emphasizes quality and patient focus, striving to improve the quality of life for patients suffering from eye-related issues.

22. Théa Pharma Italia

• Website: thea.it
• Ownership type: Family Owned
• Headquarters: Milan, Lombardy, Italy
• Employee distribution: Italy 91%, Other 9%
• Founded year: 2012
• Headcount: 51-200
• LinkedIn: thea-farma

Théa Pharma Italia, founded in 2012 and based in Milan, is a family-owned pharmaceutical company dedicated to ophthalmology. The company specializes in a wide array of products, including pharmaceuticals, medical devices, and nutritional supplements, all aimed at addressing various eye conditions such as dry eye, glaucoma, and ocular infections. With a strong focus on research and innovation, Théa Pharma Italia is recognized for its preservative-free formulations, which enhance patient comfort and adherence to treatment. The company serves healthcare professionals and patients alike, striving to improve eye health and quality of life through effective and innovative solutions. Their commitment to the field is further demonstrated by their educational initiatives and partnerships aimed at advancing ocular health.

23. ReBio

• Website: rebiopharma.com
• Ownership type: Venture Capital
• Headquarters: Raisio, Southwest Finland, Finland
• Latest funding: Other (Grant), $457,000, January 2020
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: rebio-technologies-limited

ReBio Pharma, founded in 2015 and based in Raisio, Finland, is a biotechnology firm dedicated to developing innovative treatments for chronic eye diseases. The company leverages its proprietary SiSu® technology to create sustained release formulations that enhance patient adherence and improve treatment outcomes. ReBio's primary focus is on conditions such as glaucoma and diabetic macular edema, which are prevalent and challenging to manage. The company has made strides in its development pipeline, including formulations for latanoprost and dexamethasone, aimed at transforming the standard of care in ocular therapies. ReBio has also received funding, including a grant from Business Finland, to advance its SiSu® platform, underscoring its commitment to addressing unmet clinical needs in ophthalmology. With a team of experienced professionals and a scientific advisory board composed of experts in the field, ReBio is positioned to make significant contributions to ocular drug delivery.

24. Laboratoires KÔL

• Website: laboratoires-kol.com
• Ownership type: Private
• Headquarters: Clermont-Ferrand, Auvergne-Rhône-Alpes, France
• Employee distribution: France 100%
• Founded year: 2020
• Headcount: 1-10
• LinkedIn: laboratoires-kol

Laboratoires KÔL, founded in 2020 and based in Clermont-Ferrand, France, is a private pharmaceutical company dedicated to the field of ophthalmology. The company focuses on developing innovative therapeutic solutions aimed at addressing unmet medical needs in eye care. Their product offerings include anti-rejection eye drops specifically designed for patients undergoing corneal transplants. This specialization highlights their commitment to improving patient outcomes and supporting healthcare professionals with effective treatment options. With a small team of around 18 employees, Laboratoires KÔL operates entirely within France, emphasizing their local expertise and dedication to quality in the development of their products. The company actively seeks partnerships to enhance their growth and expand their reach in the ophthalmic market.

25. NuVision Biotherapies Ltd

• Website: nu-vision.co.uk
• Ownership type: Venture Capital
• Headquarters: Nottingham, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 91%, Canada 9%
• Latest funding: $2.5M, July 2021
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: nuvision-ophthalmics-ltd

NuVision Biotherapies Ltd, founded in 2015 and based in Nottingham, UK, is a biotechnology firm dedicated to developing innovative therapies for ocular surface diseases. The company manufactures products such as Omnigen, a human amniotic membrane-derived matrix that aids in the healing of ophthalmic wounds, and OmniLenz, a bespoke bandage contact lens that allows for suture-free transplantation of Omnigen. Their patented Tereo process ensures that the natural barrier function of the amniotic membrane is preserved, enhancing the healing process. NuVision has received funding amounting to approximately £2.5 million, which supports their research and development efforts. They are actively involved in clinical studies and have presented findings at various ophthalmology conferences, showcasing the efficacy of their products in treating conditions like dry eye disease. Their commitment to advancing ocular care through innovative solutions makes them a notable player in the ophthalmology sector.

26. Sophia

• Website: sophialab.com
• Ownership type: Private
• Headquarters: Zapopan, Jalisco, Mexico
• Employee distribution: Mexico 74%, Colombia 8%, Ecuador 4%, Other 13%
• Founded year: 1946
• Headcount: 501-1000
• LinkedIn: laboratoriossophia

Laboratorios Sophia, founded in 1946 and based in Zapopan, Jalisco, Mexico, is a private pharmaceutical company dedicated to the field of ophthalmology. With a workforce of approximately 1,411 employees, the company develops and manufactures a range of prescription and over-the-counter products designed to enhance visual health. Their product portfolio addresses various eye conditions, catering to both healthcare professionals and patients. Sophia places a strong emphasis on research and development, ensuring that their products meet high-quality standards and comply with international regulations. The company is committed to innovation, continuously seeking to improve their offerings and expand their impact in the ophthalmic market. Their operations extend beyond Mexico, with a presence in several Latin American countries, reflecting their ambition to serve a broader audience in the field of eye care.

27. Neurotech Pharmaceuticals, Inc.

• Website: neurotechpharmaceuticals.com
• Ownership type: Private Equity
• Headquarters: Cumberland, Rhode Island, United States (USA)
• Employee distribution: United States (USA) 98%, Other 2%
• Latest funding: Series B, $35.0M, November 2006
• Founded year: 1995
• Headcount: 51-200
• LinkedIn: neurotechpharmaceuticals

Neurotech Pharmaceuticals, Inc., based in Cumberland, Rhode Island, is a private equity-backed biotechnology firm founded in 1995. The company is dedicated to developing transformative therapies for chronic retinal diseases, with a particular emphasis on its proprietary Encapsulated Cell Therapy (ECT) platform. This innovative technology enables the sustained release of therapeutic proteins, such as Ciliary Neurotrophic Factor (CNTF), directly into the eye, offering potential long-term treatment solutions for conditions like Macular Telangiectasia. Neurotech is actively engaged in clinical research, with ongoing trials aimed at demonstrating the safety and efficacy of its therapies. The company has received significant funding, amounting to $35 million in a Series B round in 2006, which has supported its research and development efforts. Neurotech's commitment to patient engagement and collaboration with the medical community further underscores its role in advancing ocular drug delivery solutions.

28. Valitor

• Website: valitorbio.com
• Ownership type: Venture Capital
• Headquarters: Berkeley, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $28.0M, October 2022
• Founded year: 2010
• Headcount: 1-10
• LinkedIn: valitor-inc-

Valitor is a biotechnology company based in Berkeley, California, founded in 2010. The company specializes in developing innovative medicines for vision-threatening diseases and cancer therapies. Valitor leverages its proprietary multivalent biopolymer technology to create long-acting treatments that aim to improve patient outcomes. Their primary focus is on enhancing the efficacy and compliance of therapeutic interventions in ophthalmology. Valitor's lead candidate, VLTR-557, is designed for the treatment of wet age-related macular degeneration (AMD), a condition that typically requires frequent intravitreal injections. By potentially reducing the frequency of these injections to twice a year, Valitor aims to address issues of patient compliance and treatment efficacy. The company has received significant funding, with a Series B round totaling $28 million in October 2022, indicating investor confidence in their approach and technology. Valitor's commitment to improving patient care in ophthalmology positions it as a notable entity in the ocular drug delivery sector.

Ocular Drug Delivery Insights: Key Companies

Want to Find More Ocular Drug Delivery Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!